Search
MDX-214
go.drugbank.com/drugs/DB06110ExperimentalMDX-214 consists of recombinant human epidermal growth factor (EGF) genetically linked to a fully human antibody fragment that is designed to activate cytotoxic killing of cancer cells by immune effector cells. It is developed for the tr...
Cobalt
go.drugbank.com/drugs/DB14574ApprovedWithdrawnIt is used in nuclear weapons, alloys, and pigments. Deficiency in animals leads to anemia; its excess in humans can lead to erythrocytosis.
Butaperazine
go.drugbank.com/drugs/DB13213ApprovedButaperazine was approved in 1967 [L5143], and possibly discontinued in the 1980s [T397].
FX06
go.drugbank.com/drugs/DB05685InvestigationalFX06 has proven safe in acute and subchronic toxicological studies and recently entered clinical development. It is being developed by Fibrex Medical Inc. … FX06 is a naturally occurring peptide derived from the neo-N-terminus of fibrin (Bbeta(15-42)). It prevents leukocyte migration through the gap junctions of endothelial cells.
Carfentanil
go.drugbank.com/drugs/DB01535IllicitInvestigationalVet approvedCarfentanil was first synthesized in 1974 by a team of chemists at Janssen Pharmaceutica which included Paul Janssen. … Carfentanil is intended for large-animal use only as its extreme potency makes it inappropriate for use in humans.
Cyfluthrin
go.drugbank.com/drugs/DB13828ExperimentalCategories: Compounds used in a research, industrial, or household settingStevioside
go.drugbank.com/drugs/DB16882InvestigationalCategories: Compounds used in a research, industrial, or household settingCypermethrin
go.drugbank.com/drugs/DB13721InvestigationalCategories: Compounds used in a research, industrial, or household setting